https://www.selleckchem.com/pr....oducts/lificiguat-yc
As a co-primary outcome, changes from baseline in sub-maximal exercise capacity will be assessed by the 6-minute walking test. Patient- and physician-reported questionnaires will be used to assess QoL, changes in signs and symptoms of HF and sleep parameters. Conclusion OUTSTEP-HF will be the largest randomized trial in HF to date to use non-invasive accelerometry to assess whether treatment with sacubitril/valsartan improves patients' daily physical activity and exercise capacity compared with enalapril. This article is protect
पसंद करना
टिप्पणी
शेयर करना
